Aprogen’s ‘Remicade’ biosimilar break into KRW 1 trillion Japanese market
A ‘Remicade’ biosimilar developed by Aprogen has made a stepping stone to enter the KRW 1 trillion Japanese market.
Aprogen(CEO Jae-Seop Kim), a biosimilar company, announced the company acquired approval of its Remicade biosimilar(Japanese code name: NI-071) developed by the company from the Mi...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.